查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1806516

肝病藥物市場按疾病類型、治療類型、給藥途徑、藥物類別、最終用戶和分銷管道分類－2025-2030 年全球預測

Liver Diseases Therapeutics Market by Disease Type, Therapy Type, Route Of Administration, Drug Class, End User, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計肝病藥物市場規模2024年將達187.6億美元，2025年將達202.6億美元，2030年將達300億美元，複合年成長率為8.13%。

主要市場統計數據
基準年2024年 187.6億美元
預計2025年 202.6億美元
預測年份 2030 300億美元
複合年成長率（%） 8.13%

深入調查應對肝病挑戰的治療策略的現狀和未來潛力

肝病的盛行率和複雜性日益增加，亟需開發能有效應對慢性和急性肝病的創新治療策略。傳統治療方法依賴抗病毒藥物和支持治療，但近年來，對纖維化機制、免疫調節和細胞再生的深刻洞察正在推動重大轉變。本簡介探討了跨學科研究、尖端生物技術平台和以患者為中心的框架如何融合，重塑治療格局。

最近的科學突破和以患者為中心的創新如何重新定義肝病治療的治療方法和結果

過去十年，科學突破催化了人們對肝病理解和管理方式的變革性轉變。基因療法的創新釋放了改變潛在遺傳易感性的潛力，而細胞和再生療法的進步則提供了恢復肝功能的策略。同時，微生物組調節療法的引入正在重新定義肝病治療模式，透過利用腸肝軸溝通來抑制發炎和纖維化。

評估 2025 年美國關稅對肝病藥物研發、供應鏈和可近性的深遠影響

2025年美國關稅的實施，為全球肝病治療藥物供應鏈帶來了新的複雜性。包括用於基因和細胞治療的專用生物成分和試劑在內的國際原料正面臨越來越大的成本壓力。隨著製造成本的上升，相關人員面臨著在不影響品質或可及性的情況下保持有競爭力的價格的挑戰。

透過對疾病類型、治療方式、給藥途徑、藥物類別、使用者偏好和分銷管道進行多維細分，發現關鍵見解

準確了解患者亞群對於制定肝病治療性介入至關重要。基於疾病類型的細分涵蓋了從酒精性肝病到慢性病毒感染疾病（例如乙肝和丙肝）、肝細胞癌和膽管​​癌的亞型，以及日益頻譜的非酒精性肝病等所有疾病類型。每種疾病類型都有其獨特的病理學機制和臨床管理考慮因素。

檢驗影響美洲、中東和非洲以及亞太地區肝病治療創新、取得和採用的區域動態和獨特促進要素

區域動態對肝病藥物的採用、開發和可近性有著巨大的影響。在美洲，強大的法律規範和成熟的臨床試驗網路正在加速先進生技藥品和基因療法的普及。醫療保健系統日益重視基於價值的醫療方案，這推動了對能夠比現有標準療法具有明顯臨床和經濟效益的療法的需求。

介紹透過研究和合作推動全球肝病治療領域創新、協作和策略成長的最具影響力的組織

肝病治療格局正在由主要企業塑造，他們透過廣泛的研究管道、策略夥伴關係和有針對性的收購推動創新，而新興生物技術公司則專注於高影響力的利基領域，例如遺傳代謝疾病的基因校正和肝癌的個人化免疫療法。

產業領導者面臨的策略挑戰是如何利用新興機會、降低風險並推動肝病藥物開發和交付的永續成長

產業領導者必須果斷行動，抓住肝病治療領域的新興機會。首先，投資靈活的生產平台可以緩解供應鏈中斷，並提高對關稅造成的成本壓力的應對力。各機構應評估能夠透過風險共用模式共同開發細胞和基因療法的夥伴關係，以在控制成本的同時加速臨床進展。

綜合主要觀察和策略考慮，強調創新治療方法、協作努力和政策考量在推進肝病治療中的關鍵作用。

本執行摘要概述了影響肝病治療當前和未來的關鍵趨勢、它們對關稅、細分細微差別、區域促進因素和關鍵組織策略的影響。先進的生物平台、基因編輯技術和以患者為中心的交付模式的融合正在重塑從病毒性肝炎到複雜肝細胞癌的治療可能性。

目錄

第1章 引言

第2章 分析方法

第3章執行摘要

第4章 市場概述

第5章市場動態

  • 引入針對遺傳性肝病的基因編輯療法，並提高遞送載體的安全性
  • 肝病發生率上升推動治療需求
  • 整合人工智慧平台最佳化非酒精性脂肪性肝炎臨床試驗
  • 新型調控途徑支持以細胞為基礎的肝功能衰竭和肝硬化治療創新
  • 以患者為中心的遠端監控解決方案的成長，用於早期發現和管理肝臟併發症
  • 創業投資激增推動早期肝臟治療
  • 製藥和生物技術公司合作加速開發潛在的肝纖維化治療方法
  • 晚期肝細胞癌的小分子和生物製藥聯合治療的發展
  • 政府措施和公眾意識促進肝病的早期發現
  • 使用多組體學物標記開發個人化醫療管道以預測患者在 NASH 試驗中的反應

第6章 市場洞察

  • 波特五力分析
  • PESTEL分析

第7章：美國關稅的累積影響（2025年）

第 8 章：依疾病類型分類的肝病藥物市場

  • 酒精性肝臟疾病
  • B型肝炎
  • C型肝炎
  • 肝癌
    • 膽管癌
    • 肝細胞癌
  • 非酒精性脂肪肝

第9章肝病藥物市場（依治療類型）

  • 生物免疫治療
  • 基於細胞的再生療法
  • 基因治療
  • 微生物組調節療法
  • 小分子藥物

第 10 章肝病藥物市場（依給藥途徑）

  • 靜脈
  • 口服
  • 皮下

第 11 章：肝病藥物市場（依藥物類別）

  • 抗纖維化
    • Pirfenidone
    • 辛妥珠單抗
  • 抗病毒藥物
    • 干擾素
    • NS5A抑制劑
    • NS5B聚合酵素抑制劑
    • 核苷酸/核苷類似物
    • 蛋白酶抑制劑
  • 化療
  • 皮質類固醇
  • 免疫抑制劑
  • 單株抗體

第12章肝病藥物市場（依最終用戶）

  • 診所
  • 居家醫療
  • 醫院

第13章肝病藥物市場（依通路）

  • 醫院藥房
  • 網路藥局
  • 零售藥局

14.美洲肝病藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

15.歐洲、中東和非洲肝病藥物市場

  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非
  • 丹麥
  • 荷蘭
  • 卡達
  • 芬蘭
  • 瑞典
  • 奈及利亞
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波蘭
  • 瑞士

16.亞太地區肝病藥物市場

  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 印尼
  • 泰國
  • 菲律賓
  • 馬來西亞
  • 新加坡
  • 越南
  • 台灣

第17章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Gilead Sciences, Inc.
    • AbbVie Inc.
    • Merck & Co., Inc.
    • Bristol-Myers Squibb Company
    • Johnson & Johnson Services Inc.
    • F. Hoffmann-La Roche Ltd.
    • Pfizer Inc.
    • Novartis AG
    • GlaxoSmithKline plc
    • Intercept Pharmaceuticals, Inc. by Alfasigma SpA
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
    • Vertex Pharmaceuticals Incorporated
    • AstraZeneca PLC
    • CH Boehringer Sohn AG & Co. KG
    • Eli Lilly and Company
    • Genfit SA
    • Astellas Pharma Inc.
    • Moderna, Inc.
    • Alnylam Pharmaceuticals, Inc.

第18章 研究人工智慧

第19章 研究統計

第20章 研究聯絡人

第21章 研究報導

第22章 附錄

Product Code: MRR-437A5D08AE2A

The Liver Diseases Therapeutics Market was valued at USD 18.76 billion in 2024 and is projected to grow to USD 20.26 billion in 2025, with a CAGR of 8.13%, reaching USD 30.00 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 18.76 billion
Estimated Year [2025] USD 20.26 billion
Forecast Year [2030] USD 30.00 billion
CAGR (%) 8.13%

An In-Depth Exploration of the Current State and Future Potential in Therapeutic Strategies for Addressing Liver Disease Challenges

The escalating prevalence and complexity of liver diseases present an urgent imperative for innovative therapeutic strategies that can effectively address the spectrum of chronic and acute hepatic conditions. While traditional approaches have long relied on antiviral agents and supportive care, recent years have witnessed a profound shift driven by deeper insights into fibrotic mechanisms, immune modulation, and cellular regeneration. This introduction explores how multidisciplinary research, advanced biotechnology platforms, and patient-centered frameworks are converging to reshape the therapeutic landscape.

Throughout this report, attention is devoted to understanding how novel platforms-ranging from next-generation biologic immunotherapies to the precision of gene editing-are targeting pathophysiological pathways with unprecedented specificity. As the pipeline expands, comprehensive analyses will examine factors such as the evolving regulatory environment, supply chain resilience in light of new tariff policies, and synergies between established pharmaceutical players and emerging biotech innovators.

By presenting an integrated overview of strategic dynamics and emerging opportunities, this section sets the stage for a deeper exploration of transformative shifts, tariff implications, segmentation insights, and regional drivers that collectively inform strategic decision-making in the field of liver disease therapeutics.

How Recent Scientific Breakthroughs Coupled with Patient-Centric Innovations Are Redefining Therapeutic Approaches and Outcomes in Liver Disease Care

Over the past decade, scientific breakthroughs have catalyzed transformative shifts in how liver diseases are understood and managed. Innovations in gene therapy are unlocking the potential to correct underlying genetic predispositions, while advancements in cell-based and regenerative therapies are offering strategies to restore hepatic function. Concurrently, the introduction of microbiome-modulating therapies is redefining paradigms by harnessing gut-liver axis communications to attenuate inflammation and fibrosis.

In addition to technological leaps, patient-centric approaches are gaining prominence. Personalized immunotherapeutic regimens, informed by individual biomarker profiles, are enhancing efficacy and reducing adverse events. Furthermore, strategic alliances between pharmaceutical companies and academic research centers are accelerating translational efforts, resulting in streamlined clinical development pathways and more robust evidence generation.

As a result of these converging forces, liver disease therapeutics are transitioning from reactive symptom management toward proactive disease modification and potential reversal of hepatic damage. This section examines the catalysts driving this evolution, including shifts in regulatory expectations, expanded access programs, and the rising importance of real-world evidence in shaping therapeutic value propositions.

Assessing the Far-Reaching Consequences of the 2025 United States Tariff Measures on the Development, Supply Chains, and Accessibility of Liver Disease Treatments

The introduction of United States tariff measures in 2025 has introduced new complexities into the global supply chains for therapeutic agents targeting liver conditions. Raw materials sourced from overseas, including specialized biologic components and reagents for gene and cell therapies, have experienced increased cost pressures. As manufacturing expenses rise, stakeholders face challenges in maintaining competitive pricing structures without compromising quality or accessibility.

Moreover, these tariffs have prompted companies to reassess their sourcing strategies, with some opting to diversify suppliers or establish local production capabilities. Such shifts carry implications for production timelines, regulatory compliance, and inventory management. In parallel, research collaborations that depend on cross-border exchanges of proprietary materials and technologies are navigating a more intricate tariff landscape that demands enhanced logistical coordination.

Despite these headwinds, the tariff environment has also spurred greater investment in domestic manufacturing infrastructure and encouraged the exploration of alternative raw-material platforms. By evaluating the cumulative impact of these measures, industry leaders can develop resilient strategies that safeguard continuity of supply, optimize cost structures, and ensure ongoing patient access to critical liver disease therapies.

Unveiling Critical Insights from Multi-Dimensional Segmentation Across Disease Types, Therapeutic Modalities, Administration Routes, Drug Classes, User Settings, and Distribution Channels

A nuanced understanding of patient subpopulations is foundational to tailoring therapeutic interventions for liver diseases. Segmentation based on disease type captures the full spectrum from Alcoholic Liver Disease to chronic viral infections such as Hepatitis B and Hepatitis C, as well as hepatocellular and cholangiocarcinoma subtypes of liver cancer and the increasingly prevalent Non-Alcoholic Liver Disease. Each of these categories presents unique pathophysiological mechanisms and clinical management considerations.

Equally critical is analyzing the therapeutic modalities under investigation. Biologic immunotherapies are leveraging checkpoint inhibition and cytokine modulation, while cell-based and regenerative approaches seek to replace or repair damaged hepatic tissue. Gene therapies are poised to address inherited metabolic disorders, and microbiome-modulating interventions aim to restore gut-liver axis equilibrium. Meanwhile, the continued refinement of small-molecule compounds ensures a diverse arsenal against fibrotic and inflammatory pathways.

Routes of administration influence both patient adherence and pharmacokinetic profiles, with intravenous infusions facilitating high-dose or acute interventions, oral formulations providing convenience for chronic regimens, and subcutaneous injections offering a middle ground between efficacy and ease of use. Alongside these considerations, drug classes such as antifibrotic agents-encompassing molecules like pirfenidone and simtuzumab-and a range of antiviral compounds, including interferons and NS5A inhibitors, each play distinct roles in interrupting disease progression.

Finally, understanding the contexts in which therapies are delivered is essential. End users span from specialized clinics to home care settings and hospital environments, necessitating flexible treatment protocols and support infrastructures. Distribution channels, whether via hospital pharmacies, online dispensaries, or retail outlets, further shape access dynamics and patient experiences.

Examining Regional Dynamics and Unique Drivers Across the Americas, Europe Middle East & Africa, and Asia-Pacific That Influence Therapeutic Innovation, Access, and Adoption in Liver Disease Care

Regional dynamics exert a powerful influence on the adoption, development, and accessibility of liver disease therapies. In the Americas, strong regulatory frameworks and established clinical trial networks have accelerated the introduction of advanced biologics and gene therapies. Healthcare systems are increasingly focused on value-based care initiatives, driving demand for treatments that can demonstrate clear clinical and economic benefits over existing standards.

Europe, the Middle East, and Africa present a diverse landscape shaped by varying healthcare infrastructures and policy environments. Within this region, collaborative consortia have facilitated cross-border clinical studies, while multinational reimbursement pathways continue to evolve. Emerging economies are investing in expanded diagnostic and treatment capacities, creating new opportunities for therapies targeting both viral hepatitis and non-alcoholic steatohepatitis.

In Asia-Pacific, robust government support for research and development, combined with high prevalence rates of both viral and metabolic liver diseases, has cultivated a fertile environment for innovation. Local biotech enterprises are partnering with global pharmaceutical leaders to co-develop novel interventions, and patient access programs are adapting to the unique socioeconomic conditions across the region.

Together, these regional insights underscore the importance of tailored strategies that align regulatory, economic, and healthcare delivery considerations with the specific needs and drivers of each market.

Profiling the Most Influential Organizations Driving Innovation, Partnerships, and Strategic Growth in the Global Liver Disease Therapeutics Arena Through Research and Collaborations

The liver disease therapeutics landscape is shaped by a constellation of leading companies that drive innovation through expansive research pipelines, strategic partnerships, and targeted acquisitions. Established pharmaceutical entities continue to leverage their global development capabilities to advance large-scale clinical programs, while emerging biotechs are focusing on high-impact niches such as gene correction for inherited metabolic disorders and personalized immunotherapies for liver cancer.

Collaborative networks between academic institutions and industry players are increasingly prolific, enabling the rapid translation of preclinical discoveries into early-phase clinical trials. In parallel, alliances with contract manufacturing organizations are enhancing production scalability for complex biologics and cell therapies. The pursuit of orphan drug designations and accelerated approval pathways further illustrates how companies are navigating regulatory landscapes to bring breakthrough treatments to patients more swiftly.

Innovation is complemented by strategic investments in advanced manufacturing technologies, including closed-system bioreactors and automated cell processing, which collectively reduce production bottlenecks and improve batch consistency. Concurrently, players across the spectrum are exploring digital health integrations-from remote patient monitoring to AI-driven biomarker analysis-that have the potential to refine clinical development and broaden access.

Through a combination of in-house research excellence, external collaborations, and forward-looking technology adoption, these key companies are at the forefront of transforming liver disease treatment paradigms.

Strategic Imperatives for Industry Leaders to Capitalize on Emerging Opportunities, Mitigate Risks, and Foster Sustainable Growth in Liver Disease Therapeutic Development and Delivery

Industry leaders must act decisively to capitalize on emerging opportunities within liver disease therapeutics. First, investing in flexible manufacturing platforms will mitigate supply chain disruptions and enhance responsiveness to tariff-induced cost pressures, thereby safeguarding uninterrupted patient access. Organizations should evaluate partnerships that enable co-development of cell and gene therapies with shared risk models to accelerate clinical advancement while controlling expenses.

Second, adopting a patient-centric development framework will strengthen real-world evidence generation, optimize trial design, and improve adherence. Tailoring protocols to accommodate home care administration and digital health support can differentiate offerings and align with evolving care delivery trends. In parallel, leveraging biomarkers to stratify patient populations will increase the probability of clinical success and support value-based pricing discussions.

Third, proactive engagement with regulatory agencies across key regions will facilitate alignment on accelerated approval pathways and post-market surveillance requirements. Companies should establish cross-functional regulatory task forces that integrate global policy insights, ensuring that development strategies are robust and adaptable.

By executing on these strategic imperatives, industry leaders can drive sustainable growth, enhance therapeutic impact, and maintain a competitive advantage in the rapidly evolving field of liver disease care.

The insights presented in this report are built upon a rigorous, multi-layered research methodology designed to ensure accuracy, relevance, and comprehensive coverage of the liver disease therapeutics landscape. Primary research forms the backbone of our analysis, incorporating in-depth interviews with key opinion leaders, clinical investigators, regulatory specialists, and senior executives within pharmaceutical and biotech companies.

Complementing these qualitative insights, secondary research draws from peer-reviewed journals, clinical trial registries, patent filings, and regulatory documents to validate pipeline developments and technology trends. Data from publicly available corporate reports, scientific conferences, and institutional repositories further enrich the contextual understanding of competitive dynamics.

Analytical frameworks, including SWOT assessments and PESTEL evaluations, have been applied to interpret strategic positioning, innovation drivers, and external influences such as tariff policies. Triangulation of qualitative and quantitative data ensures that findings are cross-verified and free from bias.

Finally, ongoing validation through expert workshops and scenario analyses enhances the robustness of conclusions and recommendations, providing stakeholders with a dependable foundation for strategic planning and investment decisions.

Synthesis of Key Findings and Strategic Reflections That Highlight the Pivotal Role of Innovative Therapies, Collaborative Efforts, and Policy Considerations in Advancing Liver Disease Treatment

This executive summary has synthesized the critical trends, tariff implications, segmentation nuances, regional drivers, and key organizational strategies that define the current and future state of liver disease therapeutics. The convergence of advanced biologic platforms, gene editing technologies, and patient-centric delivery models is reshaping treatment possibilities for conditions ranging from viral hepatitis to complex hepatocellular carcinomas.

By examining the cumulative impact of United States tariff measures, this report underscores the importance of resilient supply chain strategies and diversified manufacturing approaches. Segmentation analyses reveal distinct treatment pathways tailored to varied disease subtypes, therapeutic mechanisms, and delivery environments, while regional insights highlight the need for market-specific strategies informed by local healthcare infrastructures and regulatory landscapes.

Strategic recommendations emphasize the value of collaborative development models, patient-data integration, and proactive regulatory engagement. Together, these elements form a cohesive roadmap for stakeholders to navigate challenges, seize opportunities, and drive continued innovation in liver disease care.

In conclusion, the accelerated pace of scientific and policy evolution calls for decisive, informed action to translate research breakthroughs into tangible clinical benefits and deliver sustainable value to patients and healthcare systems alike.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Adoption of gene editing therapies for hereditary liver disorders with improving delivery vector safety profiles
  • 5.2. Increasing prevalence of liver diseases drives therapeutic need
  • 5.3. Integration of artificial intelligence platforms in optimizing nonalcoholic steatohepatitis clinical trials
  • 5.4. Emerging regulatory pathways support cell-based therapeutic innovations for liver failure and cirrhosis
  • 5.5. Growth of patient-centric remote monitoring solutions for early detection and management of hepatic complications
  • 5.6. Surging venture capital investments fuel early-stage liver therapeutics
  • 5.7. Collaborations between pharmaceutical companies and biotech firms to accelerate liver fibrosis drug candidate pipelines
  • 5.8. Growth of combination small molecule and biologic therapies for advanced hepatocellular carcinoma
  • 5.9. Government initiatives and public awareness drive early detection of liver diseases
  • 5.10. Development of personalized medicine pipelines using multiomic biomarkers to predict patient responses in NASH trials

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Liver Diseases Therapeutics Market, by Disease Type

  • 8.1. Introduction
  • 8.2. Alcoholic Liver Disease
  • 8.3. Hepatitis B
  • 8.4. Hepatitis C
  • 8.5. Liver Cancer
    • 8.5.1. Cholangiocarcinoma
    • 8.5.2. Hepatocellular Carcinoma
  • 8.6. Non Alcoholic Lever Disease

9. Liver Diseases Therapeutics Market, by Therapy Type

  • 9.1. Introduction
  • 9.2. Biologic Immunotherapies
  • 9.3. Cell-Based & Regenerative Therapy
  • 9.4. Gene Therapy
  • 9.5. Microbiome-Modulating Therapies
  • 9.6. Small-Molecule Drugs

10. Liver Diseases Therapeutics Market, by Route Of Administration

  • 10.1. Introduction
  • 10.2. Intravenous
  • 10.3. Oral
  • 10.4. Subcutaneous

11. Liver Diseases Therapeutics Market, by Drug Class

  • 11.1. Introduction
  • 11.2. Antifibrotic
    • 11.2.1. Pirfenidone
    • 11.2.2. Simtuzumab
  • 11.3. Antivirals
    • 11.3.1. Interferons
    • 11.3.2. NS5A Inhibitors
    • 11.3.3. NS5B Polymerase Inhibitors
    • 11.3.4. Nucleotide/Nucleoside Analogues
    • 11.3.5. Protease Inhibitors
  • 11.4. Chemotherapeutic
  • 11.5. Corticosteroids
  • 11.6. Immunosuppressants
  • 11.7. Monoclonal Antibody

12. Liver Diseases Therapeutics Market, by End User

  • 12.1. Introduction
  • 12.2. Clinic
  • 12.3. Home Care Settings
  • 12.4. Hospital

13. Liver Diseases Therapeutics Market, by Distribution Channel

  • 13.1. Introduction
  • 13.2. Hospital Pharmacy
  • 13.3. Online Pharmacy
  • 13.4. Retail Pharmacy

14. Americas Liver Diseases Therapeutics Market

  • 14.1. Introduction
  • 14.2. United States
  • 14.3. Canada
  • 14.4. Mexico
  • 14.5. Brazil
  • 14.6. Argentina

15. Europe, Middle East & Africa Liver Diseases Therapeutics Market

  • 15.1. Introduction
  • 15.2. United Kingdom
  • 15.3. Germany
  • 15.4. France
  • 15.5. Russia
  • 15.6. Italy
  • 15.7. Spain
  • 15.8. United Arab Emirates
  • 15.9. Saudi Arabia
  • 15.10. South Africa
  • 15.11. Denmark
  • 15.12. Netherlands
  • 15.13. Qatar
  • 15.14. Finland
  • 15.15. Sweden
  • 15.16. Nigeria
  • 15.17. Egypt
  • 15.18. Turkey
  • 15.19. Israel
  • 15.20. Norway
  • 15.21. Poland
  • 15.22. Switzerland

16. Asia-Pacific Liver Diseases Therapeutics Market

  • 16.1. Introduction
  • 16.2. China
  • 16.3. India
  • 16.4. Japan
  • 16.5. Australia
  • 16.6. South Korea
  • 16.7. Indonesia
  • 16.8. Thailand
  • 16.9. Philippines
  • 16.10. Malaysia
  • 16.11. Singapore
  • 16.12. Vietnam
  • 16.13. Taiwan

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Gilead Sciences, Inc.
    • 17.3.2. AbbVie Inc.
    • 17.3.3. Merck & Co., Inc.
    • 17.3.4. Bristol-Myers Squibb Company
    • 17.3.5. Johnson & Johnson Services Inc.
    • 17.3.6. F. Hoffmann-La Roche Ltd.
    • 17.3.7. Pfizer Inc.
    • 17.3.8. Novartis AG
    • 17.3.9. GlaxoSmithKline plc
    • 17.3.10. Intercept Pharmaceuticals, Inc. by Alfasigma S.p.A.
    • 17.3.11. Sanofi SA
    • 17.3.12. Takeda Pharmaceutical Company Limited
    • 17.3.13. Vertex Pharmaceuticals Incorporated
    • 17.3.14. AstraZeneca PLC
    • 17.3.15. C. H. Boehringer Sohn AG & Co. KG
    • 17.3.16. Eli Lilly and Company
    • 17.3.17. Genfit S.A.
    • 17.3.18. Astellas Pharma Inc.
    • 17.3.19. Moderna, Inc.
    • 17.3.20. Alnylam Pharmaceuticals, Inc.

18. ResearchAI

19. ResearchStatistics

20. ResearchContacts

21. ResearchArticles

22. Appendix

LIST OF FIGURES

  • FIGURE 1. LIVER DISEASES THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 16. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 18. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 20. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 24. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 25. LIVER DISEASES THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. LIVER DISEASES THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 27. LIVER DISEASES THERAPEUTICS MARKET: RESEARCHAI
  • FIGURE 28. LIVER DISEASES THERAPEUTICS MARKET: RESEARCHSTATISTICS
  • FIGURE 29. LIVER DISEASES THERAPEUTICS MARKET: RESEARCHCONTACTS
  • FIGURE 30. LIVER DISEASES THERAPEUTICS MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. LIVER DISEASES THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ALCOHOLIC LIVER DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ALCOHOLIC LIVER DISEASE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HEPATITIS B, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HEPATITIS C, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HEPATITIS C, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CHOLANGIOCARCINOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CHOLANGIOCARCINOMA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NON ALCOHOLIC LEVER DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NON ALCOHOLIC LEVER DISEASE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGIC IMMUNOTHERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGIC IMMUNOTHERAPIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CELL-BASED & REGENERATIVE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CELL-BASED & REGENERATIVE THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY MICROBIOME-MODULATING THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY MICROBIOME-MODULATING THERAPIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY SMALL-MOLECULE DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY SMALL-MOLECULE DRUGS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY PIRFENIDONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY PIRFENIDONE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY SIMTUZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY SIMTUZUMAB, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY INTERFERONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NS5A INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NS5A INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NUCLEOTIDE/NUCLEOSIDE ANALOGUES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NUCLEOTIDE/NUCLEOSIDE ANALOGUES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPEUTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPEUTIC, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CLINIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CLINIC, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 89. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 91. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 93. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 95. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 96. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 97. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2024 (USD MILLION)
  • TABLE 98. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2025-2030 (USD MILLION)
  • TABLE 99. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 100. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 101. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 102. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 103. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 104. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 105. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2024 (USD MILLION)
  • TABLE 106. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2025-2030 (USD MILLION)
  • TABLE 107. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
  • TABLE 108. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2030 (USD MILLION)
  • TABLE 109. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 110. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 111. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 112. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 113. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 115. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 116. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 117. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2024 (USD MILLION)
  • TABLE 118. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2025-2030 (USD MILLION)
  • TABLE 119. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 120. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 121. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 122. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 123. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 124. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 125. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2024 (USD MILLION)
  • TABLE 126. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2025-2030 (USD MILLION)
  • TABLE 127. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
  • TABLE 128. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2030 (USD MILLION)
  • TABLE 129. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 130. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 131. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 132. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 133. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 134. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 135. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 136. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 137. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2024 (USD MILLION)
  • TABLE 138. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2025-2030 (USD MILLION)
  • TABLE 139. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 140. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 141. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 142. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 143. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 144. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 145. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2024 (USD MILLION)
  • TABLE 146. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2025-2030 (USD MILLION)
  • TABLE 147. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
  • TABLE 148. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2030 (USD MILLION)
  • TABLE 149. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 150. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 151. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 152. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 153. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 154. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 155. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2024 (USD MILLION)
  • TABLE 156. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2025-2030 (USD MILLION)
  • TABLE 157. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 158. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 159. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 160. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 161. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 162. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 163. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2024 (USD MILLION)
  • TABLE 164. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2025-2030 (USD MILLION)
  • TABLE 165. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
  • TABLE 166. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2030 (USD MILLION)
  • TABLE 167. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 168. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 169. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 170. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 171. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 173. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2024 (USD MILLION)
  • TABLE 174. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2025-2030 (USD MILLION)
  • TABLE 175. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 177. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 178. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 179. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 180. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 181. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2024 (USD MILLION)
  • TABLE 182. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2025-2030 (USD MILLION)
  • TABLE 183. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
  • TABLE 184. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2030 (USD MILLION)
  • TABLE 185. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 186. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 187. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 188. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 189. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 191. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2024 (USD MILLION)
  • TABLE 192. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2025-2030 (USD MILLION)
  • TABLE 193. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 195. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 196. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 197. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 198. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 199. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2024 (USD MILLION)
  • TABLE 200. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2025-2030 (USD MILLION)
  • TABLE 201. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
  • TABLE 202. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2030 (USD MILLION)
  • TABLE 203. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 204. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 205. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 206. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2025-2030 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2025-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2030 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 227. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 229. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2024 (USD MILLION)
  • TABLE 230. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2025-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 234. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 236. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2024 (USD MILLION)
  • TABLE 238. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2025-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
  • TABLE 240. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2030 (USD MILLION)
  • TABLE 241. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 243. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 244. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 245. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 247. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2024 (USD MILLION)
  • TABLE 248. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2025-2030 (USD MILLION)
  • TABLE 249. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 251. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 252. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 253. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 254. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 255. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2024 (USD MILLION)
  • TABLE 256. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2025-2030 (USD MILLION)
  • TABLE 257. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
  • TABLE 258. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2030 (USD MILLION)
  • TABLE 259. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 261. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 262. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 263. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 265. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2024 (USD MILLION)
  • TABLE 266. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2025-2030 (USD MILLION)
  • TABLE 267. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 269. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 270. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 271. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 272. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 273. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2024 (USD MILLION)
  • TABLE 274. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2025-2030 (USD MILLION)
  • TABLE 275. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
  • TABLE 276. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2030 (USD MILLION)
  • TABLE 277. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 279. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 280. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 281. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 283. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2024 (USD MILLION)
  • TABLE 284. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2025-2030 (USD MILLION)
  • TABLE 285. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 287. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 288. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 289. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 290. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 291. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2024 (USD MILLION)
  • TABLE 292. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2025-2030 (USD MILLION)
  • TABLE 293. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
  • TABLE 294. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2030 (USD MILLION)
  • TABLE 295. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 296. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 297. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 298. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 299. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 300. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 301. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2024 (USD MILLION)
  • TABLE 302. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2025-2030 (USD MILLION)
  • TABLE 303. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 305. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 306. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 307. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 308. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 309. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIF